TW200640502A - Tablets with improved drug substance dispersibility - Google Patents

Tablets with improved drug substance dispersibility

Info

Publication number: TW200640502A
Authority: TW; Taiwan
Prior art keywords: drug substance; tablets; improved drug; carrier; dispersibility
Prior art date: 2005-02-25

Application number

TW095106135A

Other languages

English (en)

Inventor

Nathalie Bernigal

Eric Garcia

Susanne Page

Joseph Tardio

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-25

Filing date

2006-02-23

Publication date

2006-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200640502(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-23 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-12-01 Publication of TW200640502A publication Critical patent/TW200640502A/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW095106135A 2005-02-25 2006-02-23 Tablets with improved drug substance dispersibility TW200640502A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05101458		2005-02-25

Publications (1)

Publication Number	Publication Date
TW200640502A true TW200640502A (en)	2006-12-01

Family

ID=36406213

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095106135A TW200640502A (en)	2005-02-25	2006-02-23	Tablets with improved drug substance dispersibility

Country Status (20)

Country	Link
US (2)	US20060193910A1 (zh)
EP (2)	EP2281556A1 (zh)
JP (1)	JP2008531509A (zh)
KR (1)	KR20070094666A (zh)
CN (1)	CN101128189A (zh)
AR (1)	AR055561A1 (zh)
AU (1)	AU2006218193A1 (zh)
BR (1)	BRPI0606187A2 (zh)
CA (1)	CA2598762A1 (zh)
CR (1)	CR9292A (zh)
IL (1)	IL185011A0 (zh)
MA (1)	MA29268B1 (zh)
MX (1)	MX2007009571A (zh)
NO (1)	NO20074092L (zh)
NZ (1)	NZ560232A (zh)
RU (1)	RU2007129642A (zh)
TW (1)	TW200640502A (zh)
UA (1)	UA90708C2 (zh)
WO (1)	WO2006089674A2 (zh)
ZA (1)	ZA200706495B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
WO2007122635A2 (en) *	2006-04-26	2007-11-01	Astron Research Limited	Controlled release formulation comprising anti-epileptic drugs
CA2702055C (en) *	2007-10-10	2017-12-12	Mallinckrodt Baker, Inc.	Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) *	2007-10-10	2010-03-04	Mallinckrodt Baker, Inc.	Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
DE102008047910A1 (de)	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010084066A1 (en) *	2009-01-23	2010-07-29	F. Hoffmann-La Roche Ag	Pharmaceutical composition comprising aleglitazar
PH12012500887A1 (en)	2009-11-18	2016-08-26	Helsinn Healthcare Sa	Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
CN102641302B (zh) *	2011-02-18	2016-01-20	上海张江中药现代制剂技术工程研究中心	一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) *	2011-05-04	2012-12-10	Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН)	Средство для профилактики и лечения атеросклероза
CN104784239B (zh) *	2015-04-28	2017-12-26	新乡医学院第一附属医院	一种快速溶出的珍菊降压片及其制备工艺
KR20170003414A (ko) *	2015-06-30	2017-01-09	(주)아모레퍼시픽	속붕해형 과립환 모발 세정용 조성물
WO2017003137A1 (ko) *	2015-06-30	2017-01-05	(주)아모레퍼시픽	속붕해형 과립환 모발 세정용 조성물
CA3043609A1 (en) *	2016-11-16	2018-05-24	Abide Therapeutics, Inc.	Pharmaceutical formulations
LT3541807T (lt)	2016-11-16	2021-12-27	H. Lundbeck A/S	Magl inhibitoriaus kristalinė forma
CN109701441B (zh) *	2018-12-16	2021-04-09	桂林理工大学	一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) *	2020-02-19	2021-05-21	台灣森本生物科技開發股份有限公司	含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) *	2020-04-27	2020-08-18	上海应用技术大学	一种通用型花肥速释片及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY110880A (en) *	1991-01-30	1999-06-30	The Wellcome Foundation Ltd	Water-dispersible tablets
EP0916346A3 (en)	1991-09-20	2000-12-06	Glaxo Group Limited	NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
NZ293606A (en)	1994-09-22	1998-06-26	Akzo Nobel Nv	Preparation of pharmaceutical dosage units of a steroidal progestogen by mixing with water and granulating the solution
US6106865A (en) *	1995-01-09	2000-08-22	Edward Mendell Co., Inc.	Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) *	1995-11-22	1997-10-27	Recordati Chem Pharm	Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
ATE288756T1 (de)	1996-12-02	2005-02-15	Merck Sharp & Dohme	Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
ATE285776T1 (de)	1996-12-02	2005-01-15	Merck Sharp & Dohme	Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) *	1997-08-25	2009-11-18	大正製薬株式会社	水難溶性成分を配合した固形剤
GB9825242D0 (en)	1998-11-19	1999-01-13	Cambridge Advanced Tech	Genetically modified plants with altered starch
PE20001302A1 (es) *	1998-11-27	2000-11-30	Hoffmann La Roche	Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
IL144717A0 (en)	1999-02-24	2002-06-30	Hoffmann La Roche	Phenyl-and pyridinyl derivatives
RU2236402C2 (ru)	1999-02-24	2004-09-20	Ф.Хоффманн-Ля Рош Аг	Производные 3-фенилпиридина и фармацевтическая композиция на их основе
ES2226622T3 (es)	1999-02-24	2005-04-01	F. Hoffmann-La Roche Ag	Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
EP1075525B1 (en)	1999-03-06	2004-10-06	Roche Diagnostics GmbH	Dna polymerase from pyrobaculum islandicum
US6274588B1 (en)	1999-05-31	2001-08-14	Hoffmann-La Roche Inc.	4-phenyl-pyrimidine derivatives
JO2308B1 (en)	1999-05-31	2005-09-12	اف. هوفمان- لاروش أيه جي‏	Derivatives of phenylpyrmidine
US7863331B2 (en) *	1999-07-09	2011-01-04	Ethypharm	Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) *	1999-07-09	2004-05-28	Ethypharm Lab Prod Ethiques	Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6303790B1 (en)	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
ES2208205T3 (es)	1999-11-29	2004-06-16	F. Hoffmann-La Roche Ag	2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
US6452001B2 (en)	2000-05-25	2002-09-17	Hoffmann-La Roche Inc.	Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en)	2000-06-08	2002-11-19	Hoffmann-La Roche Inc.	Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
ATE400556T1 (de)	2000-07-14	2008-07-15	Hoffmann La Roche	N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
TWI287003B (en)	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
YU39503A (sh)	2000-11-22	2006-05-25	F. Hoffmann-La Roche Ag.	Derivati pirimidina
JP4116436B2 (ja)	2000-12-14	2008-07-09	エフ．ホフマン−ラロシュアーゲー	自己乳化脂質マトリックス（ｓｅｌｍ）
US6642226B2 (en)	2001-02-06	2003-11-04	Hoffman-La Roche Inc.	Substituted phenyl-piperidine methanone compounds
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
MXPA03009720A (es)	2001-04-23	2004-01-29	Hoffmann La Roche	USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
MXPA03010321A (es)	2001-05-14	2004-02-17	Hoffmann La Roche	Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.
US20030083345A1 (en)	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en)	2001-07-31	2005-02-01	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted amides
US6667327B2 (en)	2002-02-04	2003-12-23	Hoffmann-La Roche Inc.	Pyridine amido derivatives
US6660736B2 (en)	2002-03-27	2003-12-09	Hoffmann-La Roche Inc.	Phthalimido derivatives and a process for their preparation
AU2003227614B2 (en)	2002-04-26	2008-06-26	F. Hoffmann-La Roche Ag	Isoquinoline derivatives
PL212708B1 (pl)	2002-05-29	2012-11-30	Hoffmann La Roche	Pochodne N-acyloaminobenzenu, sposób ich wytwarzania, lek zawierajacy te pochodne i zastosowanie pochodnych N-acyloaminobenzenu
KR20030095600A (ko) *	2002-06-12	2003-12-24	환인제약 주식회사	펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6951884B2 (en)	2002-06-12	2005-10-04	Hoffmann-La Roche Inc.	Fluorobenzamides and uses thereof
US6900354B2 (en)	2002-07-15	2005-05-31	Hoffman-La Roche Inc.	3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en)	2002-08-07	2005-01-25	Hoffman-La Roche Inc.	2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (es)	2002-09-20	2005-03-01	Hoffmann La Roche	Derivados de 4-pirrolidino-fenil-bencil-eter
JP2006056781A (ja) *	2002-11-15	2006-03-02	Bioserentack Co Ltd	界面活性剤を含む固形化製剤
DE60307512T2 (de)	2002-12-13	2007-02-08	F. Hoffmann-La Roche Ag	3h-chinazoline -4-on derivaten
EP1592428B1 (en)	2003-01-31	2007-07-11	F. Hoffmann-La Roche AG	New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n- 6-(1,1-dioxo-1lamda-6 -thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl -n-methyl-isobutyramide
FR2851918B1 (fr) *	2003-03-06	2006-06-16		Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) *	2004-09-30	2006-03-30	Stephen Turner	Method for improving the bioavailability of orally delivered therapeutics

2006
- 2006-02-16 RU RU2007129642/15A patent/RU2007129642A/ru not_active Application Discontinuation
- 2006-02-16 AU AU2006218193A patent/AU2006218193A1/en not_active Abandoned
- 2006-02-16 BR BRPI0606187-7A patent/BRPI0606187A2/pt not_active IP Right Cessation
- 2006-02-16 CN CNA2006800061155A patent/CN101128189A/zh active Pending
- 2006-02-16 EP EP10179258A patent/EP2281556A1/en not_active Withdrawn
- 2006-02-16 KR KR1020077019272A patent/KR20070094666A/ko not_active Ceased
- 2006-02-16 NZ NZ560232A patent/NZ560232A/en not_active IP Right Cessation
- 2006-02-16 MX MX2007009571A patent/MX2007009571A/es not_active Application Discontinuation
- 2006-02-16 WO PCT/EP2006/001395 patent/WO2006089674A2/en active Application Filing
- 2006-02-16 UA UAA200710576A patent/UA90708C2/ru unknown
- 2006-02-16 EP EP06706996A patent/EP1855655A2/en not_active Ceased
- 2006-02-16 JP JP2007556532A patent/JP2008531509A/ja active Pending
- 2006-02-16 CA CA002598762A patent/CA2598762A1/en not_active Abandoned
- 2006-02-17 US US11/357,303 patent/US20060193910A1/en not_active Abandoned
- 2006-02-23 TW TW095106135A patent/TW200640502A/zh unknown
- 2006-02-23 AR ARP060100652A patent/AR055561A1/es not_active Application Discontinuation
2007
- 2007-08-02 IL IL185011A patent/IL185011A0/en unknown
- 2007-08-03 ZA ZA200706495A patent/ZA200706495B/xx unknown
- 2007-08-07 CR CR9292A patent/CR9292A/es not_active Application Discontinuation
- 2007-08-08 NO NO20074092A patent/NO20074092L/no not_active Application Discontinuation
- 2007-08-24 MA MA30164A patent/MA29268B1/fr unknown
2009
- 2009-08-17 US US12/542,163 patent/US20090304795A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20090304795A1 (en)	2009-12-10
EP1855655A2 (en)	2007-11-21
MA29268B1 (fr)	2008-02-01
MX2007009571A (es)	2007-09-21
BRPI0606187A2 (pt)	2009-06-09
UA90708C2 (ru)	2010-05-25
US20060193910A1 (en)	2006-08-31
AU2006218193A1 (en)	2006-08-31
AR055561A1 (es)	2007-08-22
JP2008531509A (ja)	2008-08-14
WO2006089674A2 (en)	2006-08-31
CA2598762A1 (en)	2006-08-31
NO20074092L (no)	2007-09-04
RU2007129642A (ru)	2009-03-27
EP2281556A1 (en)	2011-02-09
CN101128189A (zh)	2008-02-20
WO2006089674A3 (en)	2007-02-08
IL185011A0 (en)	2007-12-03
CR9292A (es)	2010-04-21
NZ560232A (en)	2010-11-26
ZA200706495B (en)	2008-10-29
KR20070094666A (ko)	2007-09-20

Publication	Publication Date	Title
TW200640502A (en)	2006-12-01	Tablets with improved drug substance dispersibility
Li et al.	2006	In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets
WO2006078593A3 (en)	2006-09-14	Direct compression formulation and process
WO2008063910A3 (en)	2009-06-18	Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2003035051A3 (en)	2004-03-11	The use of proton sequestering agents in drug formulations
WO2009153346A3 (en)	2010-02-18	Stabilization of amorphous drugs using sponge-like carrier matrices
MX2009002757A (es)	2009-06-10	Formulacion de farmaco resistente al abuso.
WO2002074247A8 (en)	2003-01-03	Pharmaceutical formulations for sustained release
WO2006011159A3 (en)	2006-07-06	Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
UA100866C2 (ru)	2013-02-11	Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины
WO2007016388A3 (en)	2007-08-16	Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2009122301A3 (en)	2009-11-26	Rasagiline mesylate particles and process for the preparation thereof
WO2007021970A3 (en)	2008-10-09	Stable pharmaceutical formulations and methods of use thereof
WO2009074286A3 (en)	2009-07-30	Pharmaceutical formulation comprising ezetimibe
EA200900572A1 (ru)	2009-10-30	Мицеллярные наночастицы с химическими субстанциями
WO2008049633A3 (en)	2008-06-12	Spray-freeze-drying process for the preparation of pellets comprising percolation drying
EP1847260A3 (en)	2009-11-11	Solid dispersion preparation
WO2003082262A3 (en)	2004-07-29	Compositions of venlafaxine base
WO2008069938A3 (en)	2008-10-09	Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
MX2010004291A (es)	2010-08-02	Producto de dispersion solida de farmacos basados en n-aril urea.
CN106139156A (zh)	2016-11-23	一种含有喹啉衍生物或其盐的药物组合物
WO2011056785A3 (en)	2011-09-29	Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2006002077A3 (en)	2006-11-16	Stable pharmaceutical formulations of benzimidazole compounds
WO2004073652A3 (en)	2005-02-10	Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
WO2007086911A3 (en)	2008-04-17	Stable nanoparticle formulations